Key points are not available for this paper at this time.
The incidence of oropharyngeal cancer (OPC) is increasing, due mainly to a rise in Human Papilloma Virus (HPV)-mediated disease. HPV-mediated OPC has significantly better prognosis compared with HPV-negative OPC, stimulating interest in treatment de-intensification approaches to reduce long-term sequelae. Routine clinical testing frequently utilises immunohistochemistry to detect upregulation of p16 as a surrogate marker of HPV-mediation. However, this does not detect discordant p16-/HPV+ cases and incorrectly assigns p16+/HPV- cases, which, given their inferior prognosis compared to p16+/HPV+, may have important clinical implications. The biology underlying poorer prognosis of p16/HPV discordant OPC requires exploration.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jill Brooks
Yuanning Zheng
Kelly J. Hunter
Frontiers in Oncology
Stanford University
University of Birmingham
University of Warwick
Building similarity graph...
Analyzing shared references across papers
Loading...
Brooks et al. (Thu,) studied this question.
www.synapsesocial.com/papers/68e58ba1b6db643587527395 — DOI: https://doi.org/10.3389/fonc.2024.1428741